Please login to the form below

Not currently logged in
Email:
Password:

XenoPort appoints chief medical officer

Richard Kim led Tysabri programme at Biogen Idec

XenoPort has appointed Dr Richard Kim as chief medical officer and senior VP, clinical development and medical affairs.

Dr Kim has been with the US biopharma company since July 2013, when he joined as VP of medical affair, supporting the marketing of Horizant (gabapentin enacarbil) in restless legs syndrome and postherpetic neuralgia.

He joined XenoPort from Biogen Idec where he was joint programme team leader for the hugely successful multiple sclerosis (MS) treatment Tysabri (natalizumab) helping with drug's launches in markets that included the US.

Prior to joining Biogen Idec Dr Kim was with Merck Serono, serving as medical director for the phase III programme of cladribine, which failed to impress in MS.

XenoPort will look to Dr Kim's experience as it prepares to advance its drug candidate XP23829, which is being studied as a treatment for psoriasis and/or relapsing forms of MS, into phase II development.

6th February 2014

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Research Partnership

We are the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the global pharmaceutical...

Latest intelligence

Article:
The disparity of patient experiences with Crohn’s Disease in Europe and Japan...
Patient diversity in clinical trials
The pursuit of patient diversity in clinical trials
When all-inclusive isn’t an option, it’s an obligation...
Overcoming the digital patient recruitment challenges of connecting with patients
How many irrelevant experiences, ads, emails, direct messages have you rejected this week?...